Article thumbnail

Ranibizumab in neovascular age-related macular degeneration

By Kenneth T Eng and Peter J Kertes

Abstract

Neovascular age-related macular degeneration (AMD) is a visually devastating condition resulting from choroidal neovascularization and secondary photoreceptor loss. Ranibizumab and bevacizumab are medications that target vascular endothelial growth factor (VEGF). While other therapies have demonstrated some ability to reduce the risk of losing vision from neovascular AMD, most patients continue to lose some degree of central visual acuity. There is growing evidence that intravitreal administration of ranibizumab and bevacizumab is effective in significantly improving the visual acuity in patients with neovascular age-related macular degeneration

Topics: Reviews
Publisher: Dove Medical Press
OAI identifier: oai:pubmedcentral.nih.gov:2699647
Provided by: PubMed Central

Suggested articles

Citations

  1. (2003). A randomised trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer.
  2. (2006). Anecortave acetate (15 milligrams) versus photodynamic therapy for treatment of subfoveal neovascularization in age-related macular degeneration.
  3. (2006). Association for Research in Vision and Ophthalmology
  4. (2004). Bevacizumab plus irinotecan, fl uorouracil,and leucovorin for metastatic colorectal cancer.
  5. (2003). Combined photodynamic therapy with verteporfi n and intravitreal triamcinolone acetonide for choroidal neovascularization.
  6. (1999). Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125Ilabelled full-length and Fab antibodies in rhesus monkeys following intravitreal administration. Toxicol Pathol,
  7. (2006). Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (avastin).
  8. (2006). Electrophysiologic fi ndings after intravitreal bevacizumab (avastin) treatment.
  9. (2001). Eye Disease Study Research Group.
  10. (1994). Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy.
  11. (1996). Inhibition of preretinal and optic nerve head neovascularization in pigs by intravitreal triamcinolone acetonide.
  12. (1996). Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. Arch Ophthalmol,
  13. (2006). Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.
  14. (2006). Intravitreal bevacizumab (avastin) for refractory pseudophakic cystoid macular edema.
  15. (2006). Intravitreal bevacizumab (avastin) treatment of macular edema in central retinal vein occlusion: A short-term study.
  16. (2006). Intravitreal bevacizumab (avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage.
  17. (2006). Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration.
  18. (2004). Intravitreal triamcinolone acetonide and intraocular pressure.
  19. (2001). Intravitreal triamcinolone acetonide inhibits choroidal neovascularization in a laser-treated rat model. Arch Ophthalmol,
  20. (2005). Maximum tolerated dose of humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration.
  21. (2005). Optical coherence tomography fi ndings after an intravitreal injection of bevacizumab (avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging,
  22. (2004). Pegaptanib for neovascular age-related macular degeneration.
  23. (1991). Photocoagulation Study Group.
  24. (2000). Photodynamic therapy using lu-tex induces apoptosis in vitro, and its effect is potentiated by angiostatin in retinal capillary endothelial cells. Invest Ophthalmol Vis Sci,
  25. (2005). Preclinical pharmacokinetics of ranibizumab (rhuFab V2) after a single intravitreal administration. Invest Ophthalmol Vis Sci,
  26. (1992). Prevalence of age-related maculopathy: The Beaver Dam Eye Study.
  27. (2002). Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol,
  28. (2006). Randomized, controlled phase III study of ranibizumab (Lucentis) for minimally classic or occult neovascular age-related macular degeneration: Two-year effi cacy results of the MARINA study.
  29. (2006). Ranibizumab combined with verteporfi n photodynamic therapy in neovascular age-related macular degeneration.
  30. (2006). Ranibizumab for neovascular age-related macular degeneration.
  31. (2006). Ranibizumab versus verteporfi n for neovascular age-related macular degeneration.
  32. (2006). Rapid improvement of rubeosis iridis from a single bevacizumab (avastin) injection.
  33. (2006). Regression of retinal and iris neovascularization after intravitreal bevacizumab (avastin) treatment.
  34. (2005). Safety and effi cacy of intravitreal injection of ranibizumab in combination with verteporfi n PDT on experimental choroidal neovascularization in the monkey. Arch Ophthalmol,
  35. (2002). Serum and plasma levels of FGF-2 and VEGF in healthy blood donors.
  36. (1996). Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor.
  37. (2006). Surgery Trials (SST) Research Group.
  38. Surgery Trials (SST) Research Group. 2004a. Surgery for subfoveal choroidal neovascularization in age-related macular degeneration: Ophthalmic Findings;
  39. Surgery Trials (SST) Research Group. 2004b. Surgery for hemorrhagic choroidal neovascular lesions of age-related macular degeneration: Ophthalmic fi ndings;
  40. (2005). Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twelve-week results of an uncontrolled open-label clinical study.
  41. (2006). Testing of intravitreal toxicity of bevacizumab (avastin).
  42. (2003). The anecortave acetate clinical study group.
  43. (2001). The splice variants of vascular endothelial growth factor (VEGF) and their receptors.
  44. (2001). Treatment of age-related macular degeneration with photodynamic therapy (TAP) study group.
  45. (2003). Treatment of age-related macular degeneration with photodynamic therapy and verteporfi n in photodynamic therapy study groups.
  46. (2000). Triamcinolone acetonide modulates permeability and intercellular adhesion molecule-1 (ICAM1) expression of the ECV304 cell line: implications for macular degeneration. Clin Exp Immunol,
  47. (1994). Vascular endothelial growth factor in ocular fl uid of patients with diabetic retinopathy and other retinal disorders.
  48. (1996). Vascular endothelial growth factor is suffi cient to produce iris neovascularization and neovascular glaucoma in a nonhuman primate. Arch Ophthalmol,
  49. (2004). VEGF isoforms and their expression after a single episode of hypoxia or repeated fl uctuations between hyperoxia and hypoxia: relevance to clinical ROP. Mol Vis,
  50. (2003). VEGF164-mediated infl ammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization.
  51. (1999). Verteporfi n photodynamic therapy retreatment of normal retina and choroid in the cynomolgus monkey.
  52. (2006). Visual acuity outcomes following a variable-dosing regimen for ranibizumab (Lucentis) in neovascular AMD: The PrONTO study.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.